z-logo
open-access-imgOpen Access
Fatty acid binding protein 4 enhances prostate cancer progression by upregulating matrix metalloproteinases and stromal cell cytokine production
Author(s) -
Mingguo Huang,
Shintaro Narita,
Takamitsu Inoue,
Atsushi Koizumi,
Mitsuru Saito,
Hiroshi Takahashi,
Kazuyuki Numakura,
Shigeru Satoh,
Hiroshi Nanjo,
Takehiko Sasaki,
Tomonori Habuchi
Publication year - 2017
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.22908
Subject(s) - stromal cell , cancer research , downregulation and upregulation , tumor microenvironment , cytokine , prostate cancer , matrix metalloproteinase , tumor progression , metastasis , medicine , endocrinology , biology , cancer , biochemistry , tumor cells , gene
Fatty acid binding protein 4 (FABP4) is an abundant protein in adipocytes, and its production is influenced by high-fat diet (HFD) or obesity. The prostate stromal microenvironment induces proinflammatory cytokine production, which is key for the development and progression of prostate cancer (PCa). Here, we show that high FABP4 expression and its secretion by PCa cells directly stimulated PCa cell invasiveness by upregulating matrix metalloproteinases through phosphatidylinositol 3-kinase and mitogen-activated protein kinase signaling pathways. In addition, prostate stromal cells augmented PCa cell invasiveness by secreting interleukin-8 and -6 in response to FABP4. This was abrogated by the FABP4 specific inhibitor, BMS309403. Furthermore, a mouse xenograft experiment showed HFD enhanced PCa metastasis and invasiveness by the upregulation of FABP4 and interleukin-8. Clinically, the serum level of FABP4 was significantly associated with an aggressive type of PCa rather than obesity. Taken together, FABP4 may enhance PCa progression and invasiveness by upregulating matrix metalloproteinases and cytokine production in the PCa stromal microenvironment, especially under HFD or obesity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here